DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Telmisartan (Drug)

Phase: N/A

Status: Completed

Sponsored by: Boehringer Ingelheim

Summary

The primary objective of this survey is to prospectively investigate safety and efficacy in patients with hypertension treated with telmisartan in proper use in medical practice over a long period

Clinical Details

Official title: Post-Marketing Surveillance of Micardis« (Telmisartan) Special Drug Use-results Survey on Long-term Treatment

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome:

Number of patients with adverse drug reactions

Incidence of adverse drug reactions

Change in Mean systolic blood pressure (SBP)

Change in Mean diastolic blood pressure (DBP)

Secondary outcome:

Overall assessment of efficacy by investigator on 4-point scale

Change in pulse rate

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with hypertension

Exclusion Criteria: Patients with the following conditions

- Patients with a history of hypersensitivity of this product

- Women in pregnancy (included the possibility of pregnancy)

- Patients with severe biliary obstructive disorders or severe hepatic insufficiency

Locations and Contacts

Additional Information

Starting date: September 2003
Last updated: September 16, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017